Project AP14870019 – DEVELOPMENT OF A PERSONALIZED APPROACH TO EARLY DIAGNOSTICS AND PROPHYLACTICS OF PREDIABETES IN PERSONS OF THE KAZAKH POPULATION INCLUDING CLINICAL-LABORATORY, MOLECULAR AND GENETIC FEATURES OF Its DEVELOPMENT

Relevance: Diabetes mellitus (DM) and its complications are one of the world’s pressing medical and social problems. Globally, there are 352.1 million people with prediabetes and 463 million already suffering from DM[IDF, 2019]. Scientists do not exclude the connection of the debut of carbohydrate metabolism disorders with COVID-19[Guo W, et al.,2020]. In Kazakhstan at the beginning of 2021, 382,000 patients with DM are registered, the economic cost of which is more than 20.5 billion tenge/year [Almaty, 2021].

Purpose of the study: To develop a personalized approach to early diagnosis and prevention of prediabetes in the Kazakh population based on the study of clinical, metabolic and genetic markers of its development.

Expected Outcomes: In any health care system, DM and its complications is an extremely costly disease. Among all countries in the world, the USA and China have the highest expenditures on diabetes therapy (USD 295 and 109 billion, respectively). In Kazakhstan, more than 20.5 billion tenge per year is spent on outpatient drug supply for DM patients. The problem becomes especially important in the conditions of COVID-19 pandemic, as DM is one of its risk factors for the development of complications and lethality, the more so scientists do not exclude the connection of the debut of carbohydrate metabolism disorders with COVID-19.

1. Scientific publications.

The results of the research under this grant will be published (50% of the authors of the publications will be members of the research team):

• 3 (three) articles and (or) reviews in peer-reviewed scientific publications indexed in Science Citation Index Expanded of Web of Science database and (or) having CiteScore percentile in Scopus database not less than 35 (thirty-five);
• or 2 articles and (or) reviews) in foreign peer-reviewed scientific publications indexed in Science Citation Index Expanded of the Web of Science database and (or) having a CiteScore percentile in Scopus database not less than 35) – BMC Public Health, BMC Endocrine Disorders, and a patent included in the Derwent Innovations Index database (Web of Science, Clarivate Analytics) was obtained;
• as well as 1 article or review in a peer-reviewed foreign or domestic publication recommended by the UNCRC (“Science and Public Health”);
• or 2 (two) articles and (or) reviews in peer-reviewed scientific publications, included in the 1st (first) and (or) 2nd (second) quartile by impact factor in the Web of Science database and (or) having a percentile by CiteScore in the Scopus database not less than 65 (sixty-five);
• or 1 (one) article or review in a peer-reviewed scientific publication included in the 1st (first) or 2nd (second) quartile of the impact factor in the Web of Science database and (or) having a CiteScore percentile in the Scopus database not less than 65 (sixty-five) and 1 (one) patent included in the Derwent Innovations Index database (Web of Science, Clarivate Analytics);
• or 1 (one) article or review in a peer-reviewed scientific publication that is in the 1st (first) quartile for impact factor in the Web of Science database and (or) has a CiteScore percentile in the Scopus database of at least 80 (eighty);
• or 1 (one) article or review in a peer-reviewed scientific publication included in the 1st (first), 2nd (second) or 3rd (third) quartile of the impact factor in the Web of Science database and (or) having a CiteScore percentile in the Scopus database of not less than 50 (fifty), and an act of implementation (Ministry Order No. 791 of 14.11.2018) of the scientific and technical products prepared as a result of the project or a license agreement for them.
• A monograph will be published based on the results of the study;
• Materials of the research will be reported at the conferences of the republican and international level.

1. Scientific and technical products (articles, monograph, methodological recommendations, patent, act of implementation) prepared as a result of the project implementation will be implemented in the educational, scientific process of higher educational institutions of RK, in the clinical practice of primary care in the process of postgraduate training of interns, residents, masters, doctoral students, practicing physicians, as well as functioning schools of preventive medicine on the basis of medical institutions of primary health care of RK and presented in the form of documentary evidence, certified by the head of the implementing organization.

Target consumers of the results obtained: people at risk of developing type 2 diabetes mellitus.

The results of the study as intellectual property will belong to NAO “ICC” and the Grantor. To protect intellectual property, a patent, publications in journals, and a monograph will be issued.